Myeloid A20 is critical for alternative macrophage polarization and type-2 immune-mediated helminth resistance

Front Immunol. 2024 Apr 12:15:1373745. doi: 10.3389/fimmu.2024.1373745. eCollection 2024.

Abstract

Background: Protective immunity against intestinal helminths requires induction of robust type-2 immunity orchestrated by various cellular and soluble effectors which promote goblet cell hyperplasia, mucus production, epithelial proliferation, and smooth muscle contractions to expel worms and re-establish immune homeostasis. Conversely, defects in type-2 immunity result in ineffective helminth clearance, persistent infection, and inflammation. Macrophages are highly plastic cells that acquire an alternatively activated state during helminth infection, but they were previously shown to be dispensable for resistance to Trichuris muris infection.

Methods: We use the in vivo mouse model A20myel-KO, characterized by the deletion of the potent anti-inflammatory factor A20 (TNFAIP3) specifically in the myeloid cells, the excessive type-1 cytokine production, and the development of spontaneous arthritis. We infect A20myel-KO mice with the gastrointestinal helminth Trichuris muris and we analyzed the innate and adaptive responses. We performed RNA sequencing on sorted myeloid cells to investigate the role of A20 on macrophage polarization and type-2 immunity. Moreover, we assess in A20myel-KO mice the pharmacological inhibition of type-1 cytokine pathways on helminth clearance and the infection with Salmonella typhimurium.

Results: We show that proper macrophage polarization is essential for helminth clearance, and we identify A20 as an essential myeloid factor for the induction of type-2 immune responses against Trichuris muris. A20myel-KO mice are characterized by persistent Trichuris muris infection and intestinal inflammation. Myeloid A20 deficiency induces strong classical macrophage polarization which impedes anti-helminth type-2 immune activation; however, it promotes detrimental Th1/Th17 responses. Antibody-mediated neutralization of the type-1 cytokines IFN-γ, IL-18, and IL-12 prevents myeloid-orchestrated Th1 polarization and re-establishes type-2-mediated protective immunity against T. muris in A20myel-KO mice. In contrast, the strong Th1-biased immunity in A20myel-KO mice offers protection against Salmonella typhimurium infection.

Conclusions: We hereby identify A20 as a critical myeloid factor for correct macrophage polarization and appropriate adaptive mucosal immunity in response to helminth and enteric bacterial infection.

Keywords: A20 (TNFAIP3); adaptive immunity; helminth infection; immunity to parasites; innate immunity; intestinal immunity; macrophage polarization; type-2 response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cytokines / immunology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Disease Resistance* / genetics
  • Disease Resistance* / immunology
  • Immunity, Innate
  • Macrophage Activation* / immunology
  • Macrophages* / immunology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myeloid Cells / immunology
  • Th2 Cells / immunology
  • Trichuriasis* / immunology
  • Trichuris / immunology
  • Tumor Necrosis Factor alpha-Induced Protein 3* / genetics
  • Tumor Necrosis Factor alpha-Induced Protein 3* / immunology

Substances

  • Cytokines
  • Tnfaip3 protein, mouse
  • Tumor Necrosis Factor alpha-Induced Protein 3

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. IP is supported by the Belgian Foundation Against Cancer (Stichting tegen kanker) Fundamental postdoc mandate (2021-030). RG is supported by the Wellcome Trust (Z10661/Z/18/Z). Research in the GL lab is supported by VIB and research grants from Ghent University (BOF/24J/2021/052 and BOF23/GOA/001), FWO (G090322N, G026520N, G012618N, EOS-G0H2522N-40007505), the Queen Elisabeth Medical Foundation, the Charcot Foundation, the Belgian Foundation against Cancer (FAF-F/2018/1200), and the FOREUM Foundation for Research in Rheumatology. The LV lab is supported by Ghent University (BOF.GOA031-22, BOF.IBF037-20), FWO (EOS-G0H2522N-40007505), and Foundation against Cancer (Stichting tegen kanker - F/2020/1421).